MDxHealth Schedules Second EGM for Share Option Plan Approval

MDxHealth ( (MDXH) ) has issued an update.

MDxHealth SA held its ordinary annual general shareholders’ meeting (AGM) and an extraordinary general shareholders’ meeting (EGM) on May 28, 2025. During the AGM, resolutions related to the financial year ending December 31, 2024, and the renewal of board mandates were approved despite the absence of an attendance quorum. However, the EGM did not meet the required attendance quorum, prompting the scheduling of a second EGM on June 27, 2025. This meeting will address the issuance of 3,500,000 new share options under the 2025 Share Option Plan, aimed at benefiting selected participants, including company personnel and subsidiaries. The plan is expected to enhance the company’s operational capabilities by incentivizing key stakeholders.

The most recent analyst rating on (MDXH) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.

Spark’s Take on MDXH Stock

According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.

MDxHealth’s overall score reflects robust revenue growth and promising market potential in diagnostics, but is tempered by financial instability, high leverage, and valuation concerns. The positive earnings call and technical momentum offer optimism, though the financial risks need addressing for sustainable long-term growth.

To see Spark’s full report on MDXH stock, click here.

More about MDxHealth

MDxHealth SA is a company operating in the healthcare industry, primarily focused on providing advanced molecular diagnostic solutions. The company specializes in the development and commercialization of tests that aid in the diagnosis and treatment of cancer, with a particular emphasis on urological cancers.

Average Trading Volume: 70,224

Technical Sentiment Signal: Sell

Current Market Cap: $105.9M

For a thorough assessment of MDXH stock, go to TipRanks’ Stock Analysis page.